Here’s something new that’s already available: The FDA recently cleared DaylightRx, the very first prescription digital therapeutic for generalized anxiety disorder. Think of it as CBT delivered through your smartphone over a 90-day program. In clinical trials, DaylightRx demonstrated over 70% remission rates and significantly reduced anxiety in patients for up to 6 months or …
Exciting news in anxiety treatment! The FDA has granted breakthrough therapy designation to MM120, a novel LSD-based treatment for generalized anxiety disorder. Phase 2 trials showed that a single oral dose led to meaningful reductions in anxiety symptoms lasting for weeks LifeStance Health, with Phase 3 trials currently underway. What makes this particularly promising is …
A new study published in Frontiers in Public Health (January 2025) identifies key risk factors for generalized anxiety disorder (GAD) in adolescents, using machine-learning methods. Frontiers Key findings: Why this matters: Take-Home Thoughts (for Your Community):
